Bayer Pharma’s big change taking shape but won’t be complete until patients benefit, says R&D boss Christian Rommel

Bayer Pharma’s big change taking shape but won’t be complete until patients benefit, says R&D boss Christian Rommel

AskBio has an adeno-associated virus (AAV)-based gene therapy platform and has been driving Bayer’s pipeline of gene therapies that are developed across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications. Most advanced in the clinic are investigational treatments for Parkinson’s disease, Pompe disease and congestive heart failure.

https://www.thepharmaletter.com/article/bayer-pharma-s-big-change-taking-shape-but-won-t-be-complete-until-patients-benefit-says-r-d-boss-christian-rommel

Submit a Comment

Your email address will not be published. Required fields are marked *